相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial et al.
LANCET ONCOLOGY (2020)
DREAMM-9: Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM).
Saad Zafar Usmani et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).
Sagar Lonial et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM).
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
Suzanne Trudel et al.
BLOOD CANCER JOURNAL (2019)
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
Yu-Tzu Tai et al.
BLOOD (2014)